Kornimate/medical-research-clean huggingface dataset:
implementation of the start back screening tool

Conditions: Low Back Pain

Summary: the start back screening tool (sbst) has been used in different healthcare settings in order to stratify the management of patients with low back pain. however, to date, no study has investigated the feasibility of implementing the sbst in emergency departments. the objective of this study will be to test the implementation of the sbst in the stratification of patients seeking care in emergency departments.

the start back screening tool (sbst) aims to identify and stratify primary care patients by using modifiable prognostic indicators that are relevant in clinical decision making. the objective of this study will be to test the feasibility of the implementation of the sbst in the stratification of patients seeking care in emergency departments. study design: a prospective longitudinal cohort study with a 6-month follow-up. intervention: at 6-weeks after baseline consultation, patients will be targeted to the specific treatment according to their subclassification in the sbst tool: education about pain neurophysiology and physical therapy. this is the first study that will provide results about logistic processes of the implementation of the sbst in the emergency sector, present feasibility data for the conduction of a large randomized controlled trial of subgroups of low back pain.

Eligibility criteria:
inclusion criteria: * we will include patients with back pain seeking care in emergency departments exclusion criteria: * we will exclude patients with serious spinal pathologies (such as cancer, fractures, inflammatory and infectious diseases) as well as pregnant patients and patients with nerve root compromise.

Keywords: low back pain emergency feasibility implementation
hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis. a prospective observational study.

Conditions: Hepatobiliary Disease

Summary: several studies using different methodological approach have revealed incomplete, old and conflicting data on the course of hepatobiliary manifestations after surgery. authors conducted a prospective observational study to evaluate the role of lrp on the course of hepatobiliary manifestations for a better knowledge of these manifestations that is necessary to improve their management.also, to evaluate the role of surgery on prevention of liver damage from progression of the disease.

inflammatory bowel disease (ibd) prevalence is expected to reach 1% of the population in many regions over the next decade. despite the fact that the primary clinical manifestations of ibd are centred in the gastrointestinal tract, 25-40% of ibd patients develop at least one extraintestinal manifestation (eim). hepatobiliary manifestations constitute one of the most common eims in ibd . hepatobiliary manifestations are much more commonly associated with ulcerative colitis (uc) and include primary sclerosing cholangitis (psc), autoimmune hepatitis (aih), fatty liver, cholelithiasis, primary biliary cholangitis, portal vein thrombosis, and hepatic abscess. most uc patients can be managed medically, but a minority requires proctocolectomy. two-stage laparoscopic proctocolectomy (lpc) with ileal pouch-anal anastomosis (ipaa) is a cure for colitis, but its effect on hepatobiliary diseases is controversial.

Eligibility criteria:
inclusion criteria: * patients between 18-69 years, * both sex diagnosed as ulcerative colitis with at least one hepatobiliary manifestation * underwent laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis * with or without gallstones. exclusion criteria: * age\ 69 years, * alcohol abuse, * pregnancy, * severe heart failure or type ii diabetes mellitus (defined as established diagnosis, hba1c \> 6.4%, non-fasting glucose level \> 180 mg/dl, or on antidiabetic medication), * development of complications or death related to the operation of lrp , * liver toxicity of ibd-related medications., * chronic viral hepatitis, * haemochromatosis, * wilson's disease,
a prospective study of application of platelet mapping in hbv-related acute-on-chronic-liver failure in china

Conditions: Thrombelastography,Acute on Chronic Liver Failure, Platelet

Summary: ineffective hemostasis or a paradoxical prothrombotic state of acute-on-chronic liver disease (aclf) has been well established. thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. and through the platelet mapping, it can help provide a picture of patients' function of platelet. this study aims to explore the predictive role of platelet mapping in aclf prognosis, organ failure developments and short term mortality.


Eligibility criteria:
inclusion criteria: * patient with previously diagnosed or undiagnosed hbv related chronic liver disease/cirrhosis * inr≥1.5 and total bilirubin≥85μmol/l exclusion criteria: * inr≤1.5 or total bilirubin≤85μmol/l; * underlying chronic liver disease was other than chronic hbv infection related; * those who had hepatocellular carcinoma or other types of malignancies; * obstructive biliary diseases or other disease lead to bilirubin evaluation; * those who had acute hemorrhage one week before admission * those who received platelet, cryo transfusion or plasmapheresis one week before admission * using steroid or immunosuppressant or antiplatelet or anticoagulant drugs in 4 weeks * any kind of decompensation which persisted over a month * pregnancy and breastfeeding * those who received liver transplantation or kidney transplantation; * combine with other disease lead to organ failure including heart failure (nyha iv),respiratory failure（pao2\<60mmhg),renal insufficiency(ckd 5) and conscious disturbance (gcs\<8) * readmission; * death within 24 hours.

Keywords: thrombelastography,acute on chronic liver failure, platelet
pharmacogenetic determinants of treatment response in children

Conditions: All Malignancies; Children Being Treated for Catastrophic Illness

Summary: to investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates. to investigate the nature of heritability and the genetic basis of pharmacogenetic traits by studying family members of individuals with specific genotypes.

pharmacogenetics is that discipline devoted to elucidating the genetic determinants of drug response. particularly in the area of drug metabolism, many genes exhibit genetic polymorphism; that is, a stable percentage of the population (which generally differs by ethnic group) is deficient in the functional expression of the enzyme involved, and the deficiency is typically inherited as an autosomal recessive trait. with currently known polymorphisms in drug metabolism, the percentage of homozygous deficient individuals ranges from 0.3% to as many as 90% of the population, depending on the enzyme and the ethnic group. our prior studies have revealed multigenic pharmacogenetic models that are significantly predictive of various drug response phenotypes (e.g., drug resistance, drug clearance, drug toxicity, disease response) in children with all. the large number of candidate loci and the relatively small number of patients illustrate the fact that larger sample sizes are required to definitively establish these polygenic models. the fact that there were significant race/genotype interactions, such that predictions differed in whites vs blacks, highlights the need for adequate numbers of patients within racial and ethnic groups to allow differential analysis of genotypic predictors after adjusting for confounding demographic factors in pharmacogenetic studies via stratified design and analyses.

Eligibility criteria:
inclusion criteria: * any patients under evaluation/treatment at st. jude children's research hospital (sjcrh) * parents or family members of st. jude patients * non patient volunteers * all study subjects must provide informed consent for participation * assent/consent of the patient (parent) must be provided prior to attempts made by investigators to enroll a family member of a sjcrh patient exclusion criteria:

Keywords: metabolism pharmacogenetic testing
surfactant disorders and chronic lung disease

Conditions: Chronic Lung Disease

Summary: interstitial lung diseases (ild) in children represent a heterogeneous group of rare and not well defined disorders. genetic abnormalities of surfactant proteins b (sftpb) and more recently c (sftpc) have been shown to be related to these pathologies. however, variability in the lung disease phenotype suggests the involvement of other surfactant-associated genes such as abca3 (atp-binding cassette, sub-family a, member, 3). thus, the aim of this project is: 1) to assess the prevalence of sftpc mutation in children with chronic lung diseases, 2) to precise clinical and radiological features of children with sftpc mutation, and 3) to identify environmental or genetic factors that may explain the extreme variability of this disease.

the first stage of this project will be to constitute a clinical, radiological, biological database of children (1 moth-17 years) with severe respiratory distress and/or an unexplained chronic ild. mutations in sftpc, sftpb and abca3 will be further identified by sequencing and documented with using the parents blood samples.

Eligibility criteria:
inclusion criteria: * children from 1 month to 17 years old with radiological alveola-interstitial syndrome and: * oxygen weaning failure \> 1 month in term newborn babies(\>37th week of pca)or\> 40 weeks of pca in preterm babies * or * chronic respiratory disease define by chronic hypoxia and/or clinical signs of respiratory distress (cough, retractions, crackle) exclusion criteria: * informed consent denied * absence of social security

Keywords: surfactant protein c interstitial lung children
a study using artificial intelligence to identify adults with complex perianal fistulas associated with crohn's disease

Conditions: Crohn Disease; Rectal Fistula

Summary: natural language processing and machine learning are examples of artificial intelligence tools. this study will check if these tools correctly identify people with crohn's disease with complex perianal fistulas from their medical records.

this is a non-interventional, retrospective study of participants with cd and cpf in a clinical practice setting. the study will enroll approximately 100 participants. the study will have a retrospective data collection to select and analyze information from emrs processed by an ai based analytics framework that uses machine learning and nlp methodologies. all participants will be enrolled in one observational group. • participants with cd this multi-center trial will be conducted in spain. the overall duration of the study is approximately 36 months.

Eligibility criteria:
inclusion criteria: 1. cd participant diagnosed or not with cpf between january 1st 2015 and december 31st 2021. exclusion criteria: not applicable.

Keywords: drug therapy
reverse engineering of exclusive enteral nutrition

Conditions: Crohn Disease

Summary: primary: nutritional therapy in the form of a whole-food based smoothie can be used to induce remission of active crohn's disease. secondary: consuming a whole foods based smoothie will result in measurable changes to the microbiome of individuals with crohn's disease and healthy controls. the specific aims of this proposal are: 1. to develop a whole-food based smoothie, based on principles of the specific carbohydrate diet, that is comparable in macronutrients and micronutrients to formulas used for exclusive enteral nutritional (een) therapy in crohn's disease. 2. to evaluate the ability of a whole-food based smoothie to induce remission of active crohn's disease. 3. to evaluate changes to the intestinal microbiome in healthy individuals consuming a whole-food based smoothie diet.

this will be an open label, pilot study over 4 weeks in children with newly diagnosed crohn's disease treated with a smoothie designed to emulate formulas used for exclusive enteral nutritional therapy. in place of formula, whole-foods based smoothie recipes and the food to create the smoothies will be given to each participant/family. the smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition (re-een). the smoothie recipes will involve whole foods that can be blenderized to liquid consistency. similar to the formulas used for een, the smoothies will provide calories, protein, fat, and carbohydrates in a distribution to support growth and development.

Eligibility criteria:
inclusion criteria: 1. age 8 -21 years old 2. diagnosis of crohn's disease within 4 weeks of study entry 3. active crohn's disease, as defined by pediatric crohn's disease activity index (pcdai) ≥10. 4. participant capable of giving informed consent, or if a minor the parent/guardian is capable of giving informed consent exclusion criteria: 1. history of surgery for crohn's disease 2. perianal disease as part of crohn's disease phenotype 3. prior treatment with een or the specific carbohydrate for crohn's disease 4. prior treatment with any immunosuppressive medication (corticosteroids, anti-tnf-alpha agent, azathioprine, methotrexate, etc.) 5. prior treatment with antibiotics for crohn's disease 6. known allergies to any of the food components in the smoothie 7. admission to hospital due to severity of crohn's disease and associated symptoms 8. unwillingness to provide informed consent

Keywords: exclusive enteral nutrition nutrition diet inflammatory bowel disease
effects of tadalafil on lmr and mhr in patients with ed

Conditions: Erectile Dysfunction; Inflammation

Summary: the aim of the study was to investigate whether daily 5 mg tadalafil over eight weeks affects to lymphocyte/monocyte ratio (lmr) and monocyte/high-density lipoprotein ratio (mhr) in patients with erectile dysfunction (ed). thirty-one patients with organic ed and 31 healthy controls between july 2017 and november 2018 were included in this retrospective study. to avoid bias, the patients were randomly selected and the controls were also incorporated consecutively. the presence of ed was determined according to the international erectile function index-5 (iief-5). the patients and the controls were evaluated in terms of iief-5, complete blood count, serum biochemistry, lmr, and mhr.

the medical records of the heterosexual men treated with the diagnosis of organic ed in the urology department of a private hospital between july 2017 and october 2018 were evaluated retrospectively. the number of samples to be included in the study was determined by the help of the computer-assisted power analysis. random sampling was performed from all cohorts of patients with ed. thirty-one male patients between the ages of 39-65 with organic erectile dysfunction more than one year and treated with oad 5 mg dose of tadalafil for eight weeks were selected as the treatment group (group t)the patients in group t have been assessed both before (t1) and after (t2) the treatment. between the ages of 39-65, thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up were selected consecutively and the control group (group c) was formed. all subjects in the control group were sexually active men with regular monogamous heterosexual relationships during the last one year. .

Eligibility criteria:
inclusion criteria: * 39-65 years old men with ed * 39-65 years old, haelthy men * patients that have received 5 mg tadalafil/day for 8 weeks * patients with informed consent forms * patients with no missing variables exclusion criteria: * patients with systemic autoimmune and inflammatory disease, * congestive heart failure, * chronic renal failure, and chronic hepatobiliary disease, * chronic lung disease, and thyroid dysfunction, * patients with acute infection, * patients with neurological deficits, * metabolic syndrome and malignancy * patients with a history of prostate, penile or pelvic surgery or radiotherapy,, * patients receiving anticoagulant, beta-blocker, antidepressants and antipsychotics, hormonal therapy, * patients with alcohol and smoking

Keywords: erectile dysfunction lymphocyte to monocyte ratio monocyte to hdl ratio
indwelling vs immediate removal of foley catheter after robotic assisted laparoscopic sacrocolpopexy: a prospective study

Conditions: Urinary Retention

Summary: this is a prospective, comparative randomized study. our study population includes women with pelvic organ prolapse undergoing a robotic assisted laparoscopic sacrocolpopexy. the two groups will include the study group, who will have their foley catheter removed 6 hours post-op, and the control group who will have an indwelling foley catheter overnight. the two groups will be assigned according redcap randomization system.


Eligibility criteria:
inclusion criteria: * age 19-75 * pelvic organ prolapse requiring robotic assisted, laparoscopic sacrocolpopexy. exclusion criteria: * intraoperative complications necessitating a post-operative foley * cystotomy * ebl \>500ml * bowl injury * pre-operative urinary retention requiring an indwelling catheter
evaluating the use of a concentrated surfactant gel in burn patients

Conditions: Burns

Summary: this will be an observational study evaluating subject's perception of pain to dressing changes during removal and application of a surfactant gel. wound healing will also be monitored. anxiety before dressing change will be measured using a burn specific pain anxiety scale. study intervention will include cleansing the wound per the facility's standard of care, followed by applying the investigational product on the wound. this will be followed by placing an appropriate secondary dressing.


Eligibility criteria:
inclusion criteria: * subject should be an inpatient, per the two-midnight rule at the time of study initiation. * at the time of subject's admission in the hospital, duration of his or her burn wound should be \< or equal to 24 hours. * subject who has a partial thickness burn wound, or an indeterminate burn wound, or who has both these characteristics in the same wound, as determined by the site principal investigator. * subject's wound included in this study, does not require any surgical intervention. * subject is able and willing to comply with requirements of this trial protocol. * voluntarily signed informed consent obtained before any trial-related procedures are performed. * subject must be able to communicate effectively with study personnel. * subject has burn total body surface area (tbsa) between 1-20%. exclusion criteria: * subjects with electrical or radiation burns. * subjects who are pregnant, nursing or planning to become pregnant during the course of the study. * subjects who have known allergies to any ingredients in the dressings used in the study. * subjects taking opiates during the study duration. * subjects with an active diagnosis of substance use disorder within the past six months. * subjects with previously diagnosed issues with pain perception, including conditions such as peripheral neuropathy, if they will preclude accurate assessment of primary and secondary endpoints. * subjects with an active infection prior to enrollment. * subject has previous or current systemic disease(s) which, in the judgement of the investigator, is likely to interfere with treatment. subjects with well-controlled diabetes mellitus (hba1c\<8.5) shall be permitted.
encouraging judicious prescribing of opioids in los angeles county

Conditions: Substance-Related Disorders

Summary: in collaboration with the los angeles county medical examiner's office and the state of california's controlled substance utilization review and evaluation system (cures), the investigators propose to review opioid poisonings over 12 months and send letters to prescribers in california when at least one of the provider's prescription(s) was filled by a patient who died of an opioid poisoning in los angeles county. the letters will be non-judgmental and factual, explaining that a patient of the provider who was being treated with prescription narcotics died of an opioid poisoning. the letters will also encourage judicious prescribing including use of the cures system before prescribing. the investigators will evaluate physician prescribing practices over 24 months (12 months pre- and 12 months post-letter) using data from the cures database. the investigators' hypothesis is that letters will make the risk of opioids more cognitively available and that physicians will respond by prescribing opioids more carefully, resulting in fewer deaths due to misuse and more frequent use of the cures system.


Eligibility criteria:
the investigators will not be enrolling subjects. this is an evaluation of a public health intervention involving sending prescriber's factual and nonjudgmental letters, signed by the county medical examiner, that would state that a patient the provider had treated with controlled substances died of an opioid poisoning. inclusion criteria: * prescribers in california for whom at least one of their prescription(s) was filled by a patient who died of an opioid poisoning in los angeles county exclusion criteria: * prescriber is licensed outside the state of california and does not hold a california license, but the prescription was filled in california * the prescriber does not have a cures report on record * the prescriber has issued only one opioid prescription in the last 12 months since the time of the deceased death (and the prescription was to the deceased) * prescriptions with unknown drug enforcement agency (dea) number

Keywords: opioids safe prescribing
functional and structural characterization of arteriopathy in pseudoxanthoma elasticum (pxe)

Conditions: Pseudoxanthoma Elasticum

Summary: to determine the specific structural and functional features of the peripheral arteriopathy in the pseudoxanthoma elasticum (pxe), an inherited autosomal disease.

the primary objective of this study is to characterize the structural and functional characteristics of the peripheral arteries (lower and upper limbs) . a secondary objective will be to determine the arterial calcification using ct-scan as a useful tools for the diagnosis and the follow-up of this disease. data will be collected from a cohort of patients pxe monitored in our health and research pxe center at the university hospital of angers. the structural and functional variables of the distal arteries (radial and tibialis arteries) will be studied using high-resolution echography. scoring of the arterial calcium load will be determined by helicoidal ct-scan in the lower limb arteries. these variables will be compared to matched (gender and age) controls without pxe.

Eligibility criteria:
inclusion criteria: * patients with phenotypically and genetically (abcc6) proved pxe or control patients paired for age and gender * written formed consent obtained * patient affiliated to a health care system exclusion criteria: * patient with unproved pxe * pregnant woman * patient unwilling to participate to the study * not affiliated to a health care system